ClinicalTrials.Veeva

Menu

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

S

Shanghai Kechow Pharmaceuticals

Status and phase

Enrolling
Phase 2

Conditions

Plexiform Neurofibromas
Neurofibromatosis 1

Treatments

Drug: HL-085

Study type

Interventional

Funder types

Industry

Identifiers

NCT05331105
HL-085-106-II

Details and patient eligibility

About

This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)

Full description

The study includes 2 parts, phase IIa and IIb. Phase IIa is to evaluate the preliminary safety, pharmacokinetic characteristics and efficacy of HL-085, and to determine the recommended dose. To observe the 9mg dose level, approximately 15 patients will receive HL-085 at a dose of 9mg BID on a continuous dosing schedule(1 cycle=21 days). The investigator and sponsor will evaluate the safety and efficacy data to determine whether HL-085 9mg BID is appropriate. HL-085 12mg BID, 6mg BID, or other HL-085 dosing regimen will be observed as needed. A total of 15-35 patients will be enrolled in phase IIa. Phase IIb is to further evaluate the safety and efficacy of HL-085 in patients with NF1 and inoperable PN and is expected to enroll 35 patients.

Enrollment

70 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: patients must be ≥18 years of age at the time of study entry.

  • Diagnosis: Patients must have inoperable and symptomatic plexiform neurofibromas(PN), and patients must have NF1 mutation or meet at least 1 of the following NF1 diagnostic criteria:

    ① ≥6 cafe-au-lait macules ;

    ② Axillary freckling or freckling in inguinal regions;

    ③ ≥2 Lisch nodules (iris hamartomas);

    ④ A distinctive bony lesion such as dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex);

    ⑤ An optic pathway glioma;

    ⑥ First-degree relative with NF1.

  • Patients must have a measurable lesion, defined as at least 3 cm in length, amenable to MRI for efficacy assessment.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

  • Patients are able to understand and voluntarily sign a written informed consent form.

  • Patients must be willing and able to complete study procedures and follow-up examinations.

Exclusion criteria

  • Patients who are unable to undergo MRI scans (prosthesis, prosthesis, braces, etc.) or patients with lesions that cannot be evaluated by MRI.
  • Patients do not have adequate organ function.
  • Patients who are unable to take drugs orally, have difficulty swallowing or anything that may lead to inadequate drug absorption.
  • Prior treatment with MEK 1/2 inhibitors.
  • Patients known to be allergic to the ingredients or analogues of the study drug.
  • Patients with previous or current retinal diseases such as retinal vein occlusion (RVO), retinal pigment epithelium detachment (RPED), central serous retinopathy (CSR), etc. (except retinopathy caused by research diseases).
  • With infections or other uncontrolled disease.
  • Strong CYP2C9 inhibitors or inducers within 7 days before treatment of the study drug.
  • Patients who received surgery within 4 weeks or radiotherapy within 6 weeks before enrollment.
  • Patients who participated in any other clinical study treatment within 4 weeks before enrollment.
  • Patients treated with anti-NF1 treatment with unresolved chronic toxicity.
  • Clinical judgment by the investigator that the patient should not participate in the study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

70 participants in 1 patient group

HL-085
Experimental group
Description:
HL-085 9mg BID
Treatment:
Drug: HL-085

Trial contacts and locations

1

Loading...

Central trial contact

Hongqi Tian, Ph.D; Zhimei Zhu, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems